Potent Small Molecule Inhibitors for HIV-1 Protease

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	64752
Categories	Medical/Health Pharmaceuticals
Keywords	Darunavir Drug Resistance HIV/AIDS Medical/Health Pharmaceuticals Protease Inhibitors
Public Abstract	Advances in the treatment of HIV/AIDS with HIV-1 protease inhibitors in combination with reverse transcriptase inhibitors, known as highly active antiretroviral therapy (HAART), has resulted in improved life expectancy and significantly reduced HIV/AIDS-related mortality in the developed world. Unfortunately, HAART suffers from adverse drug side effects, poor oral bioavailability, and drug interactions. Also, drug-resistant HIV-1 variants have begun to emerge. Development of antiretroviral therapy with broad-spectrum activity and minimal side effects is needed for current and future HIV/AIDS treatment. Purdue University researchers have developed Darunavir, brand name Prezista, a drug used to treat HIV infection. Prezista was developed by the pharmaceutical company Tibotec and is an OARAC recommended treatment option for treatment-naive and -experienced adults and adolescents. It is also used in patients with drug-resistant HIV. The researchers have also developed a new generation of protease inhibitors that are exceedingly potent and maintain potency against multidrug resistant HIV-1 variants. Dr. Ghosh's laboratory has designed, synthesized, and evaluated several different series of compounds. These novel protease inhibitors show potent enzyme inhibitory, antiviral activity, and exceptional broad spectrum activity against highly cross-resistant mutant. Advantages: -Decreased adverse side effects -Effective against multidrug resistant HIV-1 variants -Improved bioavailability -Superior pharmacokinetic properties Potential Applications: -Medical/Healthcare -Pharmaceuticals -Drug Development -AIDS/HIV Treatment
People	Ghosh, Arun K (Project leader)
Intellectual Property	Application Date Jan 16, 2014 Type DIV-Patent Country of Filing United States Patent Number 9,359,317 Issue Date Jun 7, 2016 Application Date Jun 6, 2016 Type DIV-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jul 14, 2010 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jan 16, 2009 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Jan 16, 2009 Type NATL-Patent Country of Filing European Patent Patent Number (None) Issue Date (None) Application Date Jul 25, 2008 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jan 17, 2008 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Dec 5, 2006 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization 1801 Newman Road West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org